Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19

Andrea Cortegiani, Mariachiara Ippolito, Giulia Ingoglia, Pasquale Iozzo, Antonino Giarratano, Sharon Einav, Andrea Cortegiani, Mariachiara Ippolito, Giulia Ingoglia, Pasquale Iozzo, Antonino Giarratano, Sharon Einav

Abstract

Purpose: To assess efficacy and safety of chloroquine (CQ)/hydroxychloroquine (HCQ) for treatment or prophylaxis of COVID-19 in adult humans.

Materials and methods: MEDLINE, PubMed, EMBASE and two pre-print repositories (bioRxiv, medRxiv) were searched from inception to 8th June 2020 for RCTs and nonrandomized studies (retrospective and prospective, including single-arm, studies) addressing the use of CQ/HCQ in any dose or combination for COVID-19.

Results: Thirty-two studies were included (6 RCTs, 26 nonrandomized, 29,192 participants). Two RCTs had high risk, two 'some concerns' and two low risk of bias (Rob2). Among nonrandomized studies with comparators, nine had high risk and five moderate risk of bias (ROBINS-I). Data synthesis was not possible. Low and moderate risk of bias studies suggest that treatment of hospitalized COVID-19 with CQ/HCQ may not reduce risk of death, compared to standard care. High dose regimens or combination with macrolides may be associated with harm. Postexposure prophylaxis may not reduce the rate of infection but the quality of the evidence is low.

Conclusions: Patients with COVID-19 should be treated with CQ/HCQ only if monitored and within the context of high quality RCTs. High quality data about efficacy/safety are urgently needed.

Keywords: COVID-19; Chloroquine; Hydroxychloroquine; Mortality; SARS-CoV-2.

Conflict of interest statement

AC, GI, MI, PI, AG, SE declare to have no competing interests.

Copyright © 2020 Elsevier Inc. All rights reserved.

Figures

Fig. 1
Fig. 1
Risk of bias of RCTs assessed using Rob2 tool.
Fig. 2
Fig. 2
Risk of bias of nonrandomized studies assessed using ROBINS-I tool.

References

    1. Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA. 2020 doi: 10.1001/jama.2020.6019.
    1. Taccone F.S., Gorham J., Vincent J.L. Hydroxychloroquine in the management of critically ill patients with COVID-19: The need for an evidence base. Lancet Respir Med. 2020 doi: 10.1016/S2213-2600(20)30172-7.
    1. Cortegiani A., Ingoglia G., Ippolito M., Giarratano A., Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 doi: 10.1016/j.jcrc.2020.03.005.
    1. Cortegiani A., Ippolito M., Ingoglia G., Einav S. Chloroquine for COVID-19: Rationale, facts, hopes. Crit Care. 2020;24:210. doi: 10.1186/s13054-020-02932-4.
    1. Reeves B.C., Deeks J.J., Higgins J.P.T., Shea B., PWG Tugwell. Chapter 24: Including non-randomized studies on intervention effects. Cochrane Handb Syst Rev Interv Version 60 (Updated July 2019) Cochrane. 2019 (accessed June 9, 2020)
    1. Sterne J.A.C., Savović J., Page M.J., Elbers R.G., Blencowe N.S., Boutron I., et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366 doi: 10.1136/bmj.l4898.
    1. Sterne J.A., Hernán M.A., Reeves B.C., Savović J., Berkman N.D., Viswanathan M., et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355 doi: 10.1136/bmj.i4919.
    1. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–605. doi: 10.1007/s10654-010-9491-z.
    1. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods n.d. 10.1002/jrsm.1411.
    1. Cochrane . Cochrane Handb Syst Rev Interv Version 60 (Updated July 2019) Cochrane. 2019. Chapter 12: Synthesizing and presenting findings using other methods | Cochrane Training. (accessed June 9, 2020)
    1. Chen J., Liu D., Liu L., Liu P., Xu Q., Xia L., et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) Med Sci. 2020;49:1–10. doi: 10.3785/j.issn.1008-9292.2020.03.03.
    1. Geleris J., Sun Y., Platt J., Zucker J., Baldwin M., Hripcsak G., et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020 doi: 10.1056/nejmoa2012410.
    1. Huang M., Tang T., Pang P., Li M., Ma R., Lu J., et al. Treating COVID-19 with chloroquine. J Mol Cell Biol. 2020;00:1–4. doi: 10.1093/jmcb/mjaa014.
    1. Mahévas M., Tran V.-T., Roumier M., Chabrol A., Paule R., Guillaud C., et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2019;2020:m1844. doi: 10.1136/bmj.m1844.
    1. Rosenberg E.S., Dufort E.M., Udo T., Wilberschied L.A., Kumar J., Tesoriero J., et al. Association of Treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;12203:1–10. doi: 10.1001/jama.2020.8630.
    1. Tang W., Cao Z., Han M., Wang Z., Chen J., Sun W., et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. doi: 10.1136/bmj.m1849.
    1. Yu B., Li C., Chen P., Zhou N., Wang L., Li J., et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. 2020 doi: 10.1007/s11427-020-1732-2.
    1. Borba M.G.S., Val F.F.A., Sampaio V.S., Alexandre M.A.A., Melo G.C., Brito M., et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. JAMA Netw Open. 2020;3 doi: 10.1001/jamanetworkopen.2020.8857.
    1. Million M., Lagier J.-C., Gautret P., Colson P., Fournier P.-E., Amrane S., et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020;101738 doi: 10.1016/j.tmaid.2020.101738.
    1. Gautret P., Lagier J.C., Parola P., Hoang V.T., Meddeb L., Sevestre J., et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020;34:101663. doi: 10.1016/j.tmaid.2020.101663.
    1. Molina J.M., Delaugerre C., Le Goff J., Mela-Lima B., Ponscarme D., Goldwirt L., et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50:384. doi: 10.1016/j.medmal.2020.03.006.
    1. Mazzanti A., Briani M., Kukavica D., Bulian F., Marelli S., Trancuccio A., et al. Association of hydroxychloroquine with QTc interval in patients with COVID-19. Circulation. 2020 doi: 10.1161/CIRCULATIONAHA.120.048476.
    1. Mercuro N.J., Yen C.F., Shim D.J., Maher T.R., McCoy C.M., Zimetbaum P.J., et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for Coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020:1–6. doi: 10.1001/jamacardio.2020.1834.
    1. Chorin E., Wadhwani L., Magnani S., Dai M., Shulman E., Nadeau-Routhier C., et al. QT interval prolongation and Torsade De Pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020 doi: 10.1016/j.hrthm.2020.05.014.
    1. Maraj I., Hummel J.P., Taoutel R., Chamoun R., Workman V., Li C., et al. Incidence and determinants of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine and azithromycin. J Cardiovasc Electrophysiol. 2020 doi: 10.1111/jce.14594.
    1. Bessière F., Roccia H., Delinière A., Charrière R., Chevalier P., Argaud L., et al. Assessment of QT intervals in a case series of patients with Coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol. 2020:3–5. doi: 10.1001/jamacardio.2020.1787.
    1. van den Broek M.P.H., Möhlmann J.E., Abeln B.G.S., Liebregts M., van Dijk V.F., van de Garde E.M.W. Chloroquine-induced QTc prolongation in COVID-19 patients. Netherlands Heart J. 2020:1–4. doi: 10.1007/s12471-020-01429-7.
    1. Saleh M., Gabriels J., Chang D., Kim B.S., Mansoor A., Mahmood E., et al. The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection. Circ Arrhythmia Electrophysiol. 2020 doi: 10.1161/CIRCEP.120.008662.
    1. Peng H.C., Hussin N., Nalliah S., Ooi W.T., Tang X.Y., Zachariah S., et al. Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend. J Infect. 2020 doi: 10.1016/j.jinf.2020.05.058.
    1. Boulware D.R., Pullen M.F., Bangdiwala A.S., Pastick K.A., Lofgren S.M., Okafor E.C., et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020 doi: 10.1056/NEJMoa2016638.
    1. Burke R.M., Midgley C.M., Dratch A., Fenstersheib M., Haupt T., Holshue M., et al. Active monitoring of persons exposed to patients with confirmed COVID-19 - United States, January–February 2020. MMWR Morb Mortal Wkly Rep. 2020;69:245–246. doi: 10.15585/mmwr.mm6909e1.
    1. Nagaraja B.S., Ramesh K.N., Dhar D., Mondal M.S., Dey T., Saha S., et al. HyPE study: Hydroxychloroquine prophylaxis-related adverse events’ analysis among healthcare workers during COVID-19 pandemic: a rising public health concern. J Public Health (Bangkok) 2020 doi: 10.1093/pubmed/fdaa074.
    1. Gendelman O., Amital H., Bragazzi N.L., Watad A., Chodick G. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. Autoimmun Rev. 2020 doi: 10.1016/j.autrev.2020.102566.
    1. Konig M., Kim A.H., Scheetz M.H., Graef E.R., Liew J.W., Simard J., et al. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS- CoV-2 infection and severe COVID-19. Clin Transl Sci. 2020 doi: 10.1111/cts.12797.
    1. Chen Z., Hu J., Zhang Z., Jiang S., Han S., Yan D., et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. 2020 doi: 10.1101/2020.03.22.20040758.
    1. Carlucci P., Ahuja T., Petrilli C., Rajagopalan H., Jones S., Rahimian J. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients. MedRxiv. 2020 doi: 10.1101/2020.05.02.20080036.
    1. Seo Kim M., Jang S.-W., Park Y.-K., Kim B.-O., Hwang T.-H., Ho Kang S., et al. Treatment response to hydroxychloroquine, lopinavir-ritonavir, and antibiotics for moderate COVID-19: A first report on the pharmacological outcomes from South Korea. MedRxiv. 2020 doi: 10.1101/2020.05.13.20094193.
    1. Magagnoli J., Narendran S., Pereira F., Cummings T., Hardin J.W., Sutton S.S., et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. MedRxiv. 2020 doi: 10.1101/2020.04.16.20065920.
    1. Mallat J., Hamed F., Balkis M., Mohamed M., Mooty M., Malik A., et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study. MedRxiv. 2020 doi: 10.1101/2020.04.27.20082180.
    1. Ramireddy AHC, Reinier K, Ebinger J, Park E, Thompson M, et al. Experience with hydroxychloroquine and azithromycin in the COVID-19 pandemic: Implications for QT interval monitoring. MedRxiv n.d. 10.1101/2020.04.22.20075671.
    1. Singh S., Khan A., Chowdhry M., Chatterjee A., Shailendra A., Khan A., et al. Outcomes of hydroxychloroquine treatment among hospitalized COVID-19 patients in the United States- Real-world evidence from a healthcare network for design assistance to complete this project. MedRxiv. 2020 doi: 10.1101/2020.05.12.20099028.
    1. Ip A., Berry D.A., Hansen E., Goy A.H., Pecora A.L., Sinclaire B.A., et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients - An observational study. MedRxiv. 2020 doi: 10.1101/2020.05.21.20109207.
    1. Ahmad I., Alam M., Saadi R., Mahmud S., Saadi E. Doxycycline and hydroxychloroquine as treatment for high-risk COVID-19 patients: Experience from case series of 54 patients in long-term care facilities. MedRxiv. 2020 doi: 10.1101/2020.05.18.20066902.
    1. Freemantle N., Calvert M., Wood J., Eastaugh J., Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA. 2003;289:2554–2559. doi: 10.1001/jama.289.19.2554.
    1. Norrie J.D. Remdesivir for COVID-19: challenges of underpowered studies. Lancet. 2020 doi: 10.1016/S0140-6736(20)31023-0.
    1. Yang Z., Prinsen J.K., Bersell K.R., Shen W., Yermalitskaya L., Sidorova T., et al. Azithromycin causes a novel proarrhythmic syndrome. Circ Arrhythmia Electrophysiol. 2017;10 doi: 10.1161/CIRCEP.115.003560.
    1. Hancox J.C., Vieweg W.V.R., Hasnain M., Crouse E.L.B., Baranchuk A. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports. Ther Adv Infect Dis. 2013;1:155–165. doi: 10.1177/2049936113501816.
    1. Gautret P., Lagier J.-C., Parola P., Hoang V.T., Meddeb L., Mailhe M., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949 doi: 10.1016/j.ijantimicag.2020.105949.
    1. Mehra M.R., Desai S.S., Ruschitzka F., Patel A.N. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis. Lancet. 2020;6736:1–10. doi: 10.1016/S0140-6736(20)31180-6.
    1. WHO WHO Director-General's opening remarks at the media briefing on COVID-19 - 3 June 2020. n.d.
    1. Chief Investigators of the Randomised Evaluation of COVid-19 thERapY. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19 — RECOVERY Trial n.d. (accessed June 8, 2020).

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться